Please login to the form below

Perrigo

This page shows the latest Perrigo news and features for those working in and with pharma, biotech and healthcare.

Pfizer set to unveil Mylan merger and spin-off

The merger is likely to have knock-on effects for the other big players in the market, which in addition to Teva include Perrigo and Sandoz.

Latest news

As CEO returns, Valeant admits SEC probe

A lower-cost generic version from Perrigo "outsells the branded product by more than 250 to 1", it added.
Mylan agrees to buy Sweden's Meda for $7.2bn

Deal is set to boost its over-the-counter medicines portfolio . Mylan has shrugged off the disappointment of its failed bid for Perrigo with a $7.2bn deal to merge with ... albeit not as large as would have been forthcoming with the proposed $26bn
Mylan buys into six biosimilars, including Orencia candidate

To bolster its portfolio and pipeline, Mylan mounted a hostile takeover for generic and over-the-counter (OTC) drug specialist Perrigo last year, but failed to bring the deal to a
AstraZeneca sets sights on China with Takeda deal

The company also recently sold off US rights to gastroenterology drug Entocort (budesonide) to Perrigo for $380m, saying the product lay outside its strategic focus.
Mylan misses Perrigo takeover deadline

He added that Perrigo will go ahead with a $2bn share repurchase and said the firm plans to complete $500m of that by the end of 2015. ... Shares in Mylan ended the day on Friday up 13%, while Perrigo fell around 6%.

More from news
Approximately 9 fully matching, plus 23 partially matching documents found.

Latest Intelligence

Pharma deals continue to slide

$35bn. $7.3bn. Valeant. 40. 17.5. -56%. $28bn. ($2.4bn). Perrigo. 90. 78. ... Perrigo, like Teva and Valeant, is seeking to reduce debt. Biotech companies are also selling (or licensing) assets to stay alive.
Deal Watch February 2017

The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... 17, 900. Perrigo/ Royalty Pharma. Tysabri
Deal Watch August 2016

In contrast, in 2015 Mylan made a tender offer for Perrigo. ... Sep 15 / Hostile. Mylan. Perrigo. $26bn. Tender offer failed as Mylan shares dropped in value (Teva withdrew bid).
Deal Watch November 2015

Perrigo paid a multiple of 3.2x sales for the US rights whereas Tillotts paid 4.1x sales. ... 386. AstraZeneca. Perrigo. Acquisition - asset. Entocort (budesonide) marketed for mild to moderate Crohn's disease.
Pharma deals in August 2015

Hostile takeovers remained a topic of conversation this month as the Perrigo / Mylan saga played on; the vote taken by Mylan's shareholders on 28 August indicated support for the deal ... Perrigo had previously expressed concerns over Mylan's corporate

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

Perrigo appoints Gerresheimer’s Uwe Rohrhoff as CEO

Generic pharmaceutical company Perrigo has appointed Uwe Rohrhoff, Gerresheimer’s former chief executive officer, as its new CEO. ... Perrigo said that it suspended its search for a replacement CFO during its search for Hendrickson’s successor as CEO.
BMS appoints three independent directors

He currently serves as a director at Perrigo Company and Stamps.com, and is the former president of Capital Guardian Trust Company, and global equity portfolio manager at Capital Group.
Valeant appoints Joseph Papa to end CEO uncertainty

Valeant's month-long search for a new chief executive has ended with its selection of Perrigo's Joseph Papa to replace current CEO Michael Pearson in early May. ... He moves to Valeant from his most recent role as chief executive officer and chairman of
Perrigo promotes Neil Lister to UK leadership role

He will head up the firm's UK and Ireland business. Dublin-based Perrigo Company, has promoted Neil Lister to lead its newly-combined UK and Ireland business. ... In this role, he will be responsible for leading both the company's Omega Pharma
Keith Webber leaves FDA for Perrigo

Switches regulatory agency for biopharma company. Perrigo Company has named former US Food and Drug Administration (FDA) employee Keith Webber as head of its regulatory review process. ... The role marks a switch to the industry side of pharma for Webber,

More from appointments
Approximately 3 fully matching, plus 2 partially matching documents found.

Latest from PMHub

3 Monkeys Zeno

If you’d like to know more healthcare@3monkeyszeno.com Or visit; Merck, Bayer, Boehringher Ingelheim, Novartis, Hologic, Netflix, SilverCloud, Advanced Accelerator Applications, Perrigo.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager (PR): Great Benefits

Senior Medical Writer or Lead Medical Writer: £Competitive Salary

Experienced medical editor: Competitive salary and bonus scheme

Account Director, Healthcare Communications: Salary TBC

Scientific Director: £60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more

Account director: Competitive salary and bonus scheme

Account Director, Medical Education: Salary TBC

Digital Associate Director - Medcomms: £65000 - £80000 per annum

Account Manager: £Competitive Salary

Senior Medical Writer, MedComms Agency: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Group Director of Medical Affairs and Scientific Strategy, Medic...: Substantial six figure package

Senior External Communications Lead: £Competitive Salary

Account Director: £Competitive Salary

Brand Manager - Medium Global Pharma Company: £Competitive Financial Package

Publications director: Competitive salary and bonus scheme

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Subscribe to our email news alerts

PMHub

Add my company

Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Novo Nordisk awakens its ‘Sleeping Beauty’: Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?: Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019: OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...